Mahmoud AbdEl-Mongy1*, Elham Taha Awad2 and Fatma Mosaed3

1Microbial Biotechnology Department, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Egypt.
2Medical Microbiology and Immunology, Shibin El-kom Teaching Hospital, Monifiya, Egypt.
3Microbiology and Chemistry Department, Faculty of Science, Aswan University, Egypt.

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of Nosocomial, community acquired infections and neonatal sepsis. The Glycopeptide vancomycin was the drug of choice for treating infections. Identifying the vancomycin- resistance phenotypically and genotypically among the MRSA isolates from Shibin El-Kom teaching Hospital. All samples were collected from Neonatal intensive care unit (NICU) of Shibin El-Kom teaching hospital in Minoufiya, Egypt and identified by conventional methods. S aureus and MRSA were isolated and identified from different clinical samples using conventional methods confirmed by antibiogram of the isolates and mec A gene detection. vancomycin MIC and Vancomycin screening agar were determined following CLSI guidelines. Van A was amplified by PCR using standard primers. Out of the 200 neonates included in this study, 85% were positive growth and 15% were negative growth. Among them, 25% isolates were staphylococci, 42 isolates had nuc gene. Out of 42 S. aureus, 80.95% had mecA gene and 19.05% had not Mec A gene. The VRSA isolates had not van A gene. Vancomycin was still the most effective drug against S. aureus infection. All MRSA in Shibin El-Kom Teaching Hospital had not vanA gene.

Keywords: MRSA, VRSA, Nuc gene, Antibiotic resistance.